Subtopic Deep Dive
Pregnancy Outcomes in Rheumatic Diseases
Research Guide
What is Pregnancy Outcomes in Rheumatic Diseases?
Pregnancy Outcomes in Rheumatic Diseases examines maternal disease flares, preeclampsia risks, neonatal complications, and medication safety in rheumatoid arthritis and systemic lupus erythematosus pregnancies.
Studies analyze outcomes under antirheumatic therapies, developing preconception counseling protocols. Key guidelines include EULAR points by Skorpen et al. (2016, 1021 citations) and ACR guidelines by Sammaritano et al. (2020, 673 citations). Over 10 major papers since 2000 guide clinical management.
Why It Matters
Guidelines from Skorpen et al. (2016) and Andréoli et al. (2016) inform drug choices to minimize flares and preeclampsia in lupus pregnancies. Sammaritano et al. (2020) standardize reproductive health management, reducing preterm births in rheumatic patients. Vikse et al. (2008) link preeclampsia to end-stage renal disease, prompting long-term monitoring protocols.
Key Research Challenges
Heterogeneous Study Designs
Cross-sectional and cohort studies vary in methodology, complicating meta-analyses of flare risks (Lupattelli et al., 2014). Lack of standardized endpoints hinders outcome comparisons across rheumatoid arthritis pregnancies. Prospective data remains limited despite guidelines (Sammaritano et al., 2020).
Drug Safety Data Gaps
Placental transfer data for biologics like certolizumab is emerging but incomplete for others (Mariette et al., 2017). NSAID miscarriage risks require confirmation in rheumatic cohorts (Nielsen, 2001). Long-term neonatal effects need larger registries.
Preeclampsia Risk Prediction
Preeclampsia elevates ESRD risk post-rheumatic pregnancy, but predictive biomarkers are absent (Vikse et al., 2008). Multidisciplinary monitoring protocols lack validation in lupus patients (Andréoli et al., 2016). Individualized risk models are underdeveloped.
Essential Papers
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
Carina Gøtestam Skorpen, Maria Hoeltzenbein, Anǵela Tincani et al. · 2016 · Annals of the Rheumatic Diseases · 1.0K citations
A European League Against Rheumatism (EULAR) task force was established to define points to consider on use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Based on a s...
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
Laura Andréoli, George Βertsias, Nancy Agmon‐Levin et al. · 2016 · Annals of the Rheumatic Diseases · 852 citations
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases
Lisa R. Sammaritano, Bonnie L. Bermas, Eliza Chakravarty et al. · 2020 · Arthritis & Rheumatology · 673 citations
Objective To develop an evidence‐based guideline on contraception, assisted reproductive technologies ( ART ), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement...
Preeclampsia and the Risk of End-Stage Renal Disease
Bjørn Egil Vikse, Lorentz M. Irgens, Torbjørn Leivestad et al. · 2008 · New England Journal of Medicine · 633 citations
Although the absolute risk of ESRD in women who have had preeclampsia is low, preeclampsia is a marker for an increased risk of subsequent ESRD.
Anti-inflammatory and immunosuppressive drugs and reproduction.
Monika Østensen, Munther A. Khamashta, Michael D. Lockshin et al. · 2006 · Arthritis Research & Therapy · 527 citations
Medication use in pregnancy: a cross-sectional, multinational web-based study
Angela Lupattelli, Olav Spigset, Michael Twigg et al. · 2014 · BMJ Open · 465 citations
Objectives Intercountry comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. This study aimed to examine patterns and fa...
BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1
Julia Flint, Sonia Panchal, Alice Hurrell et al. · 2016 · Lara D. Veeken · 412 citations
Scope and purpose of the guideline Need for guidelinesThe prescribing of many drugs in pregnancy is complicated by a lack of knowledge regarding their compatibility leading to patient misinformatio...
Reading Guide
Foundational Papers
Start with Østensen et al. (2006, 527 citations) for drug-reproduction basics; Vikse et al. (2008, 633 citations) for preeclampsia-ESRD links; Janssen (2000, 285 citations) for fertility impacts.
Recent Advances
Sammaritano et al. (2020, 673 citations) ACR guidelines; Mariette et al. (2017, 373 citations) certolizumab pharmacokinetics; Flint et al. (2016, 412 citations) BSR prescribing standards.
Core Methods
Systematic reviews (Skorpen et al., 2016); prospective PK studies (Mariette et al., 2017); multinational web surveys (Lupattelli et al., 2014); population cohorts (Nielsen, 2001).
How PapersFlow Helps You Research Pregnancy Outcomes in Rheumatic Diseases
Discover & Search
Research Agent uses searchPapers and citationGraph on Skorpen et al. (2016) to map 1000+ citing works on EULAR antirheumatic drug guidelines, revealing lupus-specific extensions by Andréoli et al. (2016). exaSearch uncovers recent registry data on certolizumab transfer (Mariette et al., 2017); findSimilarPapers expands to ACR updates (Sammaritano et al., 2020).
Analyze & Verify
Analysis Agent applies readPaperContent to extract flare rates from Sammaritano et al. (2020), then verifyResponse with CoVe checks claims against Lupattelli et al. (2014). runPythonAnalysis performs meta-analysis of preeclampsia odds ratios from Vikse et al. (2008) and Nielsen (2001) using pandas; GRADE grading assesses evidence quality for NSAID miscarriage risks.
Synthesize & Write
Synthesis Agent detects gaps in long-term renal outcomes post-preeclampsia via contradiction flagging between Vikse et al. (2008) and modern guidelines. Writing Agent uses latexEditText and latexSyncCitations to draft protocols citing Skorpen et al. (2016), with latexCompile for figures and exportMermaid for disease flare timelines.
Use Cases
"Extract and plot miscarriage rates from NSAID studies in rheumatic pregnancies"
Research Agent → searchPapers(Nielsen 2001) → Analysis Agent → readPaperContent + runPythonAnalysis(pandas plot ORs) → matplotlib graph of risks vs. controls.
"Draft LaTeX guideline summary for certolizumab in lupus pregnancy"
Synthesis Agent → gap detection(Mariette 2017) → Writing Agent → latexEditText(draft) → latexSyncCitations(Skorpen 2016) → latexCompile(PDF guideline table).
"Find code for simulating rheumatic pregnancy outcome models"
Research Agent → paperExtractUrls(recent papers) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(integrate cohort simulation from Vikse 2008 data).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers from Skorpen et al. (2016) citations, generating GRADE-assessed report on drug safety. DeepScan applies 7-step analysis with CoVe checkpoints to verify preeclampsia-ESRD links in Vikse et al. (2008). Theorizer builds predictive models for flares from Østensen et al. (2006) and Sammaritano et al. (2020).
Frequently Asked Questions
What defines pregnancy outcomes in rheumatic diseases?
Disease flares, preeclampsia, preterm birth, and neonatal complications in rheumatoid arthritis and lupus under antirheumatic therapies (Skorpen et al., 2016).
What are key methods for assessing medication impact?
Prospective registries, pharmacokinetic studies like CRIB for certolizumab (Mariette et al., 2017), and guideline-based systematic reviews (Sammaritano et al., 2020).
What are the most cited papers?
Skorpen et al. (2016, 1021 citations) on EULAR drug points; Andréoli et al. (2016, 852 citations) on lupus pregnancy; Sammaritano et al. (2020, 673 citations) ACR guidelines.
What open problems persist?
Validated biomarkers for preeclampsia in rheumatic pregnancies; long-term offspring data for biologics; standardized global registries beyond European cohorts (Vikse et al., 2008).
Research Pregnancy and Medication Impact with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pregnancy Outcomes in Rheumatic Diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Pregnancy and Medication Impact Research Guide